116.20
price up icon2.65%   3.00
 
loading
Schlusskurs vom Vortag:
$113.20
Offen:
$114.555
24-Stunden-Volumen:
7.78M
Relative Volume:
0.98
Marktkapitalisierung:
$144.54B
Einnahmen:
$28.73B
Nettoeinkommen (Verlust:
$5.97B
KGV:
24.46
EPS:
4.75
Netto-Cashflow:
$9.84B
1W Leistung:
+7.37%
1M Leistung:
+9.70%
6M Leistung:
+24.85%
1J Leistung:
+51.88%
1-Tages-Spanne:
Value
$114.13
$117.60
1-Wochen-Bereich:
Value
$107.75
$117.60
52-Wochen-Spanne:
Value
$72.43
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Firmenname
Gilead Sciences Inc
Name
Telefon
(650) 574-3000
Name
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Name
Mitarbeiter
17,600
Name
Twitter
@GileadSciences
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
GILD's Discussions on Twitter

Vergleichen Sie GILD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
116.20 140.81B 28.73B 5.97B 9.84B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
812.69 723.06B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
168.30 407.97B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.28 337.08B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.70 227.39B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
71.70 314.28B 43.59B 15.04B 10.74B 3.3766

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-22 Fortgesetzt Cantor Fitzgerald Overweight
2025-03-04 Bestätigt Oppenheimer Outperform
2025-02-18 Hochstufung Deutsche Bank Hold → Buy
2025-02-13 Hochstufung DZ Bank Hold → Buy
2025-01-10 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-12-10 Fortgesetzt BofA Securities Buy
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-14 Eingeleitet Citigroup Buy
2024-11-08 Herabstufung Maxim Group Buy → Hold
2024-10-21 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-17 Eingeleitet Bernstein Outperform
2024-10-07 Hochstufung Wells Fargo Equal Weight → Overweight
2024-07-08 Hochstufung Raymond James Mkt Perform → Outperform
2024-05-01 Bestätigt Maxim Group Buy
2024-04-24 Hochstufung HSBC Securities Reduce → Hold
2024-02-22 Herabstufung Truist Buy → Hold
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-09-08 Hochstufung BofA Securities Neutral → Buy
2023-09-06 Eingeleitet HSBC Securities Reduce
2023-07-24 Bestätigt Barclays Equal Weight
2023-05-16 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-28 Fortgesetzt Piper Sandler Overweight
2023-01-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Fortgesetzt BofA Securities Neutral
2022-12-09 Herabstufung DZ Bank Buy → Hold
2022-10-31 Hochstufung Barclays Underweight → Equal Weight
2022-10-28 Bestätigt BMO Capital Markets Market Perform
2022-10-28 Bestätigt Cowen Outperform
2022-10-28 Bestätigt JP Morgan Overweight
2022-10-28 Bestätigt Jefferies Buy
2022-10-28 Hochstufung Piper Sandler Neutral → Overweight
2022-10-28 Bestätigt RBC Capital Mkts Outperform
2022-10-28 Hochstufung Truist Hold → Buy
2022-10-28 Bestätigt Wells Fargo Equal Weight
2022-10-04 Hochstufung JP Morgan Neutral → Overweight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-02-28 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-02 Bestätigt BMO Capital Markets Outperform
2022-02-02 Bestätigt BofA Securities Neutral
2022-02-02 Bestätigt RBC Capital Mkts Outperform
2022-02-02 Bestätigt Truist Hold
2022-02-02 Bestätigt Wells Fargo Equal Weight
2022-01-28 Hochstufung Argus Hold → Buy
2022-01-06 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-11-19 Fortgesetzt Piper Sandler Neutral
2021-10-20 Fortgesetzt Cowen Outperform
2021-07-30 Bestätigt BMO Capital Markets Market Perform
2021-07-30 Bestätigt RBC Capital Mkts Outperform
2021-04-01 Hochstufung Bernstein Mkt Perform → Outperform
2021-03-30 Hochstufung Redburn Neutral → Buy
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-11-03 Fortgesetzt Morgan Stanley Equal-Weight
2020-10-28 Eingeleitet UBS Neutral
2020-09-30 Fortgesetzt Jefferies Buy
2020-09-15 Hochstufung Maxim Group Hold → Buy
2020-07-31 Bestätigt Credit Suisse Neutral
2020-07-31 Bestätigt Morgan Stanley Equal-Weight
2020-07-31 Bestätigt Piper Sandler Overweight
2020-07-31 Bestätigt RBC Capital Mkts Outperform
2020-07-31 Bestätigt SunTrust Hold
2020-07-31 Bestätigt Wells Fargo Equal Weight
2020-07-20 Hochstufung Credit Suisse Underperform → Neutral
2020-06-03 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-05-26 Hochstufung SunTrust Sell → Hold
2020-05-01 Herabstufung JP Morgan Overweight → Neutral
2020-05-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-05-01 Herabstufung SunTrust Hold → Sell
2020-04-27 Herabstufung UBS Buy → Neutral
2020-04-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-04-20 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-17 Herabstufung CFRA Hold → Sell
Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

pulisher
Jul 25, 2025

European Medicines Agency Recommends Lenacapavir (Yeztugo) Injectable PrEP for HIV Prevention - Contagion Live

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences (GILD) Stock Is Up Today - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Why Gilead Sciences Stock Just Popped - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three - insights.citeline.com

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales - Benzinga

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead's twice-yearly injection for HIV prevention - Reuters

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead upgraded to Buy at Needham on new HIV drug - MSN

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences (GILD) Gains Upgrade Amid Promising HIV Drug Outlook - GuruFocus

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead stock upgraded at Needham on new HIV drug (GILD:NASDAQ) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

Analyst recommendations: Thermo Fisher Scientific, Intel, Honeywell International, Union Pacific, Gilead Sciences... - MarketScreener

Jul 25, 2025
pulisher
Jul 25, 2025

This Gilead Sciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga

Jul 25, 2025
pulisher
Jul 25, 2025

EU regulator backs Gilead’s twice-yearly injection for HIV prevention - PharmaLive

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Gets Analyst Thumbs Up On Market Potential Of HIV-Prevention Injection, But Retail’s Not Ready To Cheer Yet - Stocktwits

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead wins EU backing for twice-yearly HIV PrEP therapy - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences’ Yeztugo: A Promising Growth Driver in the HIV PrEP Market with Undervalued Potential - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention - BioSpace

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead receives positive EU opinion for twice-yearly HIV prevention drug - StreetInsider

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention - Investing.com

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead’s lenacapavir receives positive CHMP opinion for HIV prevention By Investing.com - Investing.com Nigeria

Jul 25, 2025
pulisher
Jul 25, 2025

Gilead Sciences and the Breakthrough Approval of Lenacapavir for HIV PrEP: A New Era in Global Health and Market Leadership - AInvest

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Gilead Sciences Inc. stock priceAccelerated wealth expansion - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025 - BioSpace

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Gilead Sciences Advances HIV Prevention with New Clinical Study - TipRanks

Jul 24, 2025
pulisher
Jul 23, 2025

Attorney General Jeff Jackson Secures Over $200 Million from Gilead Sciences for Paying Kickbacks to Doctors - NCDOJ (.gov)

Jul 23, 2025
pulisher
Jul 23, 2025

AG Jackson announces major settlement with Gilead Sciences over kickbacks - WLOS

Jul 23, 2025
pulisher
Jul 23, 2025

Gilead Sciences, Omnicom Group, and QuinStreet Shares Skyrocket, What You Need To Know - TradingView

Jul 23, 2025
pulisher
Jul 23, 2025

Bridging the Gap: Gilead’s Work to Help End the HIV Epidemic - The Hollywood Reporter

Jul 23, 2025
pulisher
Jul 23, 2025

Looking Back to the Future: Gilead's Long-Standing Commitment To Help End the HIV Epidemic - ACCESS Newswire

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Gilead Sciences Inc. stockHigh-octane investment gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What to Expect From Gilead Sciences’ Q2 2025 Earnings Report - MSN

Jul 23, 2025
pulisher
Jul 22, 2025

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Lobbying Update: $1,700,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study Update - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda - insights.citeline.com

Jul 22, 2025
pulisher
Jul 21, 2025

After Gilead Deal, Hookipa Hangs Up Its Hat - insights.citeline.com

Jul 21, 2025
pulisher
Jul 21, 2025

Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Hookipa, having sold off vaccines to Gilead, opts to wind down - Fierce Biotech

Jul 21, 2025
pulisher
Jul 21, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 21, 2025
pulisher
Jul 20, 2025

Gilead Sciences Inc. Stock Analysis and ForecastMarket-leading growth rates - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

Gilead’s HIV Strength Drives Gains, But Pipeline Is Key - Finimize

Jul 20, 2025
pulisher
Jul 20, 2025

Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

Is Gilead Sciences Inc. a good long term investmentFree Wealth Planning Blueprint - Jammu Links News

Jul 19, 2025
pulisher
Jul 19, 2025

Lobbying Update: $90,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq

Jul 19, 2025
pulisher
Jul 18, 2025

Gilead Sciences Trading Volume Surges 54.53% to $720 Million Ranking 154th in Market Activity - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

HOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead Sciences - Quiver Quantitative

Jul 18, 2025
pulisher
Jul 18, 2025

HOOKIPA Pharma Exits Nasdaq Market as Gilead Sciences Acquires Key Drug Programs - Stock Titan

Jul 18, 2025
pulisher
Jul 17, 2025

Foster City drugs giant Gilead to pay $202 million over alleged kickback scheme - SiliconValley.com

Jul 17, 2025

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general PFE
$24.79
price down icon 2.21%
$306.58
price down icon 0.64%
drug_manufacturers_general SNY
$50.37
price up icon 0.48%
drug_manufacturers_general MRK
$84.71
price up icon 0.71%
drug_manufacturers_general NVO
$71.70
price up icon 1.37%
Kapitalisierung:     |  Volumen (24h):